Advertisement

Reactions to Antiparkinson Agents

  • Frank L. Tornatore
  • John J. Sramek
  • Bette L. Okeya
  • Edmond H. Pi

Abstract

The cardiovascular effects are dose-related. Low doses can cause transient bradycardia; moderate or high doses can cause tachycardia, palpitation, and arrhythmias (due to blockage of vagal effects on the S-A node).

Keywords

Neuroleptic Malignant Syndrome Pyloric Stenosis Paralytic Ileus Extrapyramidal Side Effect Antiparkinson Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Suggested Readings

  1. Hall R. C. W., Feinsilver D. L., Holt R. E.: Anticholinergic psychosis: Differential diagnosis and management. Psychosomatics 22: 581–587, 1981.PubMedGoogle Scholar
  2. Hiatt R. L., Fuller I. B., Smith L., et al: Systemically administered anticholinergic drugs and intraocular pressure. Arch Ophthalmol 84: 735–740, 1970.PubMedCrossRefGoogle Scholar
  3. Lamy P. P.: Update on antiparkinsonian agents. Geriatr Pharmacol 37: 8191, 1982.Google Scholar
  4. Shimomura S. K., Siepler J. K.: Parasympatholytic cholinergic blocking agents in Knoben J. E., Anderson P. O. (eds): Handbook of Clinical Drug Data, 5th ed. Hamilton, Illinois, Drug Intelligence Publications, 1983, pp 376–378.Google Scholar
  5. Van der Kolk B. A., Shader R. I., Greenblatt D. J.: Autonomic effects of psychotropic drugs, in Lipton M. A., DiMascio A., Killam K. F. (eds): Psychopharmacology: A Generation of Progress, 2nd ed. New York, Raven Press, 1978, pp 1009–1020.Google Scholar
  6. Weiner N.: Atropine, scopolamine, and related antimuscarine drugs, in Gilman A. G., Goodman L. S., Rall T. W., Murad F. (eds): The Pharmacological Basis of Therapeutics; 7th ed. New York, Macmillan, 1985, pp 130–144.Google Scholar
  7. Zaratzian V. L.: Drug-induced dysfunctions of the autonomic nervous system, in Blum K., Manzo L. (eds): Neurotoxicology. New York, Marcel Dekker, 1985, pp 69–81.Google Scholar
  8. Goggin D. A., Solomon G. F.: Trihexyphenidyl abuse for euphorigenic effect. Am J Psychiatry 136: 459–460, 1979.PubMedGoogle Scholar
  9. Jellinek T.: Mood elevating effect of trihexyphenidyl and biperiden in individuals taking antipsychotic medication. Dis New Syst 38: 353–355, 1977.Google Scholar
  10. Jellinek T., Gardos G., Cole J. O.: Adverse effects of antiparkinson drug withdrawal. Am J Psychiatry 138: 1567–1571, 1981.PubMedGoogle Scholar
  11. MacVicar K.: Abuse of antiparkinsonian drugs by psychiatric patients. Am J Psychiatry 134: 809–811, 1977.PubMedGoogle Scholar
  12. Rubinstein J. S.: Abuse of antiparkinson drugs. J Am Med Assoc 239: 2365–2366, 1978.CrossRefGoogle Scholar
  13. Briggs G. G., Bodendorfer T. W., Freeman R. K., et al: Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Baltimore, Williams & Wilkins, 1983.Google Scholar
  14. Heironen O. P., Slone D., Shapiro S. (eds): Birth Defects and Drugs in Pregnancy. Littleton, Massachusetts, Publishing Sciences Group, 1977.Google Scholar
  15. Omnis A., Grella P. (eds): The Biochemical Effects of Drugs in Pregnancy, Vol I. New York, John Wiley, 1984.Google Scholar
  16. The Royal Women’s Hospital Reference Guide on Drugs in Pregnancy. Carlton, Victoria, R. Batagol, 1983.Google Scholar
  17. Flaherty J. A., Bellur S. N.: Mental side effects of amantadine therapy: Its spectrum and characteristics in a normal population. J Clin Psychiatry 42 (9): 344–345, 1981.PubMedGoogle Scholar
  18. Simpson D. M., Davis G. C.: Case report of neuroleptic malignant syndrome associated with withdrawal from amantadine. Am J Psychiatry 141: 796–797, 1984.PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1987

Authors and Affiliations

  • Frank L. Tornatore
    • 1
  • John J. Sramek
    • 2
  • Bette L. Okeya
    • 3
  • Edmond H. Pi
    • 4
  1. 1.University of Southern California School of PharmacyLos AngelesUSA
  2. 2.Clinical Research UnitMetropolitan State HospitalNorwalkUSA
  3. 3.Department of Pharmaceutical ServicesUCLA Medical Center and Neuropsychiatric InstituteLos AngelesUSA
  4. 4.Department of PsychiatryUniversity of Southern California School of MedicineLos AngelesUSA

Personalised recommendations